Publications by authors named "Danilo N Oliveira"
Long-COVID olfactory dysfunction: allele E4 of apolipoprotein E as a possible protective factor.
Arq Neuropsiquiatr
September 2024
Background: Olfactory dysfunction (OD) represents a frequent manifestation of the coronavirus disease 2019 (COVID-19). Apolipoprotein E (APOE) is a protein that interacts with the angiotensin-converting enzyme receptor, essential for viral entry into the cell. Previous publications have suggested a possible role of APOE in COVID-19 severity.
View Article and Find Full Text PDFArticle Synopsis
- A recent study explored the relationship between ε4 gene polymorphism, cognitive deficits, and COVID-19 in outpatient patients experiencing neurological symptoms for over three months post-infection.
- The research included 219 confirmed COVID-19 patients, finding that a significant portion reported memory issues, though only a small percentage had these concerns verified through cognitive screening tests.
- Results indicated a higher prevalence of the ε4 allele in patients with cognitive decline compared to those without, and the association remained strong even after considering sleep disorders and anxiety symptoms.
Introduction: Long-onset COVID syndrome has been described in patients with COVID-19 infection with persistence of symptoms or development of sequelae beyond 4 weeks after the onset of acute symptoms, a medium- and long-term consequence of COVID-19. This syndrome can affect up to 32% of affected individuals, with symptoms of fatigue, dyspnea, chest pain, cognitive disorders, insomnia, and psychiatric disorders. The present study aimed to characterize and evaluate the prevalence of sleep symptoms in patients with long COVID syndrome.
View Article and Find Full Text PDFLong-covid cognitive impairment: Cognitive assessment and apolipoprotein E (APOE) genotyping correlation in a Brazilian cohort.
Front Psychiatry
August 2022
Introduction: Few studies have objectively evaluated cognitive deficits after the acute phase of COVID-19 disease. Moreover, the role of apolipoprotein E (APOE) genotypes in cognitive decline in patients with COVID-19 has not been evaluated yet.
Methods: This cross-sectional study was conducted in confirmed cases of COVID-19 patients with neurological symptoms that persisted for more than 3 months from the onset.
Introduction: COVID-19 has a wide range of clinical manifestations. Neurological manifestations in COVID-19 patients were demonstrated during the pandemic, including cognitive impairment. This study aimed to determine any relationship between COVID-19 and cognitive complaints, such as dementia, mild cognitive impairment (MCI), or subjective cognitive decline (SCD).
View Article and Find Full Text PDFSARS-COV-2 infection has affected millions of individuals with a wide range of clinical manifestations, including central and peripheral nervous systems through several mechanisms. A rare but potentially severe manifestation of this virus is transverse myelitis. Herein, we report on two patients who developed paraparesis, sensory deficit, and autonomic changes on the tenth day after infection by COVID-19.
View Article and Find Full Text PDFArticle Synopsis
- Headache is a common symptom in COVID-19, affecting 6.5% to 34% of patients, but previous studies often included unverified cases or focused on severe cases.
- The study analyzed 24 laboratory-confirmed COVID-19 patients who reported headaches, revealing that the average age was 53.8 years and most had no prior history of headaches.
- The headaches were mainly bifrontal or holistic, of a pressure quality, typically began early in illness, and worsened with physical activity, but no unique characteristics were found to distinguish them from other headache causes.